R&D | December 22, 2025
Xeureka & UBE launch joint cancer drug discovery program
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
,_Thyrocare_256_384.jpg)
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhoea
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Subscribe To Our Newsletter & Stay Updated
